COST-EFFECTIVENESS OF EPISODIC OR MAINTENANCE INFLIXIMAB VERSUS STANDARD TREATMENT IN AN INCIDENCE COHORT OF CROHN'S DISEASE PATIENTS WITH 10-YEARS FOLLOW-UP

被引：0
|
作者：
Odes, S. [1 ]
Greenberg, D. [2 ]
Vardi, H. [2 ]
Friger, M. [2 ]
Stockbrugger, R. [3 ]
Munkholm, P. [4 ,5 ]
机构：
[1] Soroka Med Ctr, IL-84101 Beer Sheva, Israel
[2] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel
[3] Univ Hosp Maastricht, Maastricht, Netherlands
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Herlev Hosp, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.772
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A329 / A330
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF EVOLOCUMAB VERSUS STANDARD THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA IN PATIENTS WITH CARDIOVASCULAR DISEASE IN QATAR
    AlMukdad, S.
    Kaddoura, R.
    Arabi, A. R.
    AlMaraghi, F.
    Al Yafei, Al-Saadi S.
    Al-Badriyeh, D.
    VALUE IN HEALTH, 2022, 25 (07) : S389 - S389
  • [42] TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR USTEKINUMAB AND ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE WITH TWO-YEARS FOLLOW-UP IN THE SYMPHONY HEALTH DATABASE
    Muser, Erik
    Obando, Camilo
    Ding, Zhijie
    Slaton, Terra
    Kozma, Chris
    GASTROENTEROLOGY, 2020, 158 (06) : S959 - S959
  • [43] Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation
    Odes, Selwyn
    Vardi, Hillel
    Friger, Michael
    Wolters, Frank
    Russel, Maurice G.
    Riis, Lene
    Munkholm, Pia
    Politi, Patrizia
    Tsianos, Epameinondas
    Clofent, Juan
    Vermeire, Severine
    Monteiro, Estela
    Mouzas, Annis
    Fornaciari, Giovanni
    Sijbrandij, Jildou
    Limonard, Charles
    Van Zeijl, Gilbert
    O'Morain, Colm
    Moum, Bjorn
    Vatn, Morten
    Stockbrugger, Reinhold
    GASTROENTEROLOGY, 2006, 131 (03) : 719 - 728
  • [44] COST-EFFECTIVENESS OF INTESTINAL ULTRASOUND AS POINT-OFCARE TOOL VERSUS STANDARD CARE IN MANAGEMENT OF CROHN'S DISEASE
    Lee, Kate E.
    Dolinger, Michael T.
    Onken, Jane
    Wong, Natalie Z.
    Hong, Simon J.
    Faye, Adam S.
    GASTROENTEROLOGY, 2024, 166 (05) : S1099 - S1099
  • [45] The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort
    Odes, Selwyn H.
    Greenberg, Dan
    Vardi, Hillel
    Friger, Michael
    Stockbrugger, Reinhold W.
    Langholz, Ebbe
    Munkholm, Pia
    GASTROENTEROLOGY, 2013, 144 (05) : S639 - S639
  • [46] Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up
    Vaidya, Dhananjay
    Yanek, Lisa R.
    Moy, Taryn F.
    Pearson, Thomas A.
    Becker, Lewis C.
    Becker, Diane M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (09): : 1410 - 1415
  • [47] Risk of disease progression in patients with Crohn's disease after 7 years of follow-up in a Danish population-based inception cohort
    Burisch, J.
    Vind, I.
    Prosberg, M.
    Dubinsky, M.
    Siegel, C. A.
    Bendtsen, F.
    Vester-Andersen, M.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S440 - S440
  • [48] 10-years follow-up in patients with non-Hodgkin's lymphomas:: Results of the Munich Cancer Registry.
    Dreyling, MH
    Aydemir, Ü
    Hoelzel, D
    Hiddemann, W
    BLOOD, 2000, 96 (11) : 129A - 129A
  • [49] A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society
    Li, Ji-Bin
    Lin, Zhuo-Chen
    Wong, Martin C. S.
    Wang, Harry H. X.
    Li, Mengmeng
    Li, Su
    BMC MEDICINE, 2022, 20 (01)
  • [50] A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society
    Ji-Bin Li
    Zhuo-Chen Lin
    Martin C. S. Wong
    Harry H. X. Wang
    Mengmeng Li
    Su Li
    BMC Medicine, 20
12345